Medtronic launches heart implant for atrial fibrillation, following Boston Scientific, Abbott
The new product is aimed at closing the heart's left atrial appendage, which can help treat patients with atrial fibrillation. Rivals like Boston Scientific and Abbott already make devices for the fast-growing market. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 29, 2023 Category: Pharmaceuticals Authors: Mark Reilly Source Type: news
Less Severe Strokes With LAA Closure vs DOAC in AF? Less Severe Strokes With LAA Closure vs DOAC in AF?
Atrial fibrillation treated with left atrial appendage closure was associated with ischemic strokes that were less severe than those among similar patients treated with direct oral anticoagulation.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - November 27, 2023 Category: Primary Care Tags: Cardiology News Source Type: news
Sleep-Related Hypoxia Tied to Incident Atrial Fibrillation
WEDNESDAY, Nov. 22, 2023 -- Sleep-related hypoxia is associated with incident atrial fibrillation (AF), according to a study published online Nov. 10 in the Journal of the American Heart Association.
Catherine M. Heinzinger, D.O., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 22, 2023 Category: Pharmaceuticals Source Type: news
OCEANIC-AF Trial Sunk; Second Renal Denervation Device Approved; Strep-Stroke Link?
(MedPage Today) -- Bayer announced that the phase III OCEANIC-AF study of the oral factor XIa inhibitor asundexian was stopped early due to inferior efficacy compared with apixaban (Eliquis) for patients with atrial fibrillation (Afib).
The CDC... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 21, 2023 Category: Cardiology Source Type: news
Bleeding Higher With Standard-Dose DOACs in Nonvalvular A-Fib
THURSDAY, Nov. 16, 2023 -- For nursing home residents with nonvalvular atrial fibrillation, the rate of bleeding is higher with standard- versus reduced-dose direct acting oral anticoagulants (DOACs), according to a study published online Nov. 6 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 16, 2023 Category: Pharmaceuticals Source Type: news
ARTESIA Doesn't Answer a Common Question in Cardiology ARTESIA Doesn't Answer a Common Question in Cardiology
The trial on apixaban vs aspirin in subclinical atrial fibrillation did not provide an easy answer on whether to anticoagulate patients with these common arrhythmias, writes John Mandrola, MD.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
AHA: Apixaban Beneficial for Patients With Subclinical A-Fib
TUESDAY, Nov. 14, 2023 -- Apixaban results in a lower risk for stroke or systemic embolism than aspirin for patients with subclinical atrial fibrillation, according to a study published online Nov. 12 in the New England Journal of Medicine to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 14, 2023 Category: Pharmaceuticals Source Type: news
AF Linked to Dementia, Especially Before Age 65 Years AF Linked to Dementia, Especially Before Age 65 Years
Atrial fibrillation is linked to an increased risk for dementia, particularly when diagnosed before age 65 years, a large population-based study shows.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - November 14, 2023 Category: Primary Care Tags: Psychiatry News Source Type: news
DOAC Cuts Stroke Risk From Subclinical Afib
(MedPage Today) -- PHILADELPHIA -- For patients with subclinical atrial fibrillation (Afib, AF) detected by their pacemaker or defibrillator, direct oral anticoagulation brought their already low stroke risk even lower -- but at a cost in bleeding... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 13, 2023 Category: Cardiology Source Type: news
TIMI Study Finds New Class of Anti-Clotting Drug Reduced Bleeding Events Compared with Standard of Care in Patients with Atrial Fibrillation
The researchers found that abelacimab, a Factor XI inhibitor, at a dose of 150 mg monthly, significantly reduced bleeding compared to the standard-of-care anticoagulant, rivaroxaban. (Source: BWH News)
Source: BWH News - November 13, 2023 Category: Hospital Management Source Type: news
Double Defibrillator More Effective for Obese Afib Patients
(MedPage Today) -- PHILADELPHIA -- For atrial fibrillation (Afib) patients with obesity, a second set of defibrillation pads for dual direct current cardioversion safely improved the success of the procedure, a randomized trial showed.
Only... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 12, 2023 Category: Cardiology Source Type: news
Earlier Onset of A-Fib Linked to Risk of Developing All-Cause Dementia
THURSDAY, Nov. 9, 2023 -- Earlier onset of atrial fibrillation (AF) is associated with increased risk of developing all-cause dementia, vascular dementia (VD), and Alzheimer disease (AD), according to a study published online Nov. 8 in JAMA Network... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 10, 2023 Category: Pharmaceuticals Source Type: news
Consequences of Oral Anticoagulant Choice Magnified in the Frail
(MedPage Today) -- Older adults with atrial fibrillation (Afib, or AF), especially those with frailty, had better patient-centered outcomes taking apixaban (Eliquis) than other common oral anticoagulants (OACs), Medicare records showed.
Compared... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 9, 2023 Category: American Health Source Type: news
Outcomes of PF Ablation for AF Similar Between Sexes Outcomes of PF Ablation for AF Similar Between Sexes
Male and female patients with atrial fibrillation have similar efficacy and safety outcomes after catheter ablation using pulsed field energy, new registry data show.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - November 7, 2023 Category: Primary Care Tags: Cardiology News Source Type: news
Mandrola's Top Trials to Look for at AHA 2023 Mandrola's Top Trials to Look for at AHA 2023
Semaglutide ’s cardiovascular benefit in SELECT, another sham-PCI trial from the ORBITA investigators, and ARTESiA, which examines anticoagulation in subclinical atrial fibrillation, are the top AHA late-breakers for John Mandrola, MD.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2023 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
